Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

Hap (Robert) Sneddon FCSIHorizon's Medical MarijuanaHMMJ.TOCOMMENTApr 15, 2019

There is some downside pressure on HMMJ-T. At the $14 or $17 range there is resistance. Who knows what the effect would be if the government changes in October. [Caller asked about TLRY] He sees $34 as a target on TLRY-T as there is nothing to hold it higher.
$19.89

Stock price when the opinion was issued

$7.29

As of Jun 19, 2026. Market Open.

E.T.F.'s
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK

This asset class has been down for 5 years during a long period of investor apathy. But when an asset class has been down for longer than 3 years, you start to consider it. HMMJ has US exposure where there is growing public support for legalizing canopy. Maybe start with a small position. This is a volatile sector.

DON'T BUY
Are you investing or gambling? Some invest in hot sectors like cannabis or blockchain without understanding them. He's never owned this, because it's gambling. He avoids the sector for the same reason.
DON'T BUY
Wouldn't buy. Firstly on principle, as they're active managers. The ETF owns the good, the bad, and the ugly. There are a lot of garbagy business models and bottom feeders out there.
BUY ON WEAKNESS
The yield is not a dividend. Because of M&A, there is a capital distribution every year. Long term CBDs are going to be a big part of the future. It could be an election issue in the US. These companies don't make any money so it is speculative. He likes it longer term.
PARTIAL BUY
He started to nibble. Expect a lot of volatility. He likes it on valuation.
PARTIAL BUY
He has said for a couple of years that he wants the industry to mature. He thinks there is some value there at this point. There are really no earnings, however. Usually when a correction hits, stocks without earnings get hit first. He has been buying below $9. Don't commit a lot of money. Just nibble.
DON'T BUY
Not just discouraging performance, but catastrophic. None of these things are making any money. He won't be buying in this sector. He likes earnings.
DON'T BUY
The problem he has with this is that you can't get capacity. He stays away from it.
DON'T BUY
He's never liked marijuana stocks. The hype wasn't justified and they got way ahead of themselves. This will be regulated like alcohol which means tight returns.
DON'T BUY
Marijuana stocks There has been a sell off because of Canntrust and no one is making money. There will be a lot of research to be done on the benefits. However, the best days to make profit here are probably behind us.
BUY ON WEAKNESS
Anytime you are investing in an area with such massive potential growth opportunities, you will see volatility. If you buy a little and more yet in corrections, it is a way to play it. Wait for good stiff corrections.
BUY

HMMJ vs. HMUS. A monstrous opportunity, but you're going to suffer volatility. Go slow, get in over time, and keep it to a smaller proportion of your portfolio. Market weighted. The US exposure is to companies operating legally, and there can't be any recreational use. With HMUS, you're tapping into a bigger market. For example, Charlotte's Web is planning to sell CBD infused products through Kroeger. This scale dwarfs the whole Canadian market. Valuations are high because of the growth potential. If you're a marijuana investing aficionado, you'd want to own both.

COMMENT
Any vice will do well, and so will this. Horizon makes great ETFs. That said, ETF's aren't always the best. Instead of buying the weed basket, buy the leader--Canopy.
DON'T BUY
Companies on this don't have any earnings. With out earnings he doesn't want it.
COMMENT
How does this pay a yield if weed stocks don't? It does pay a dividend, perhaps from capital gains from buying and selling those weed stocks within the ETF. He doesn't think cannabis will be an exciting industry, but will wind up like the liquor business.